Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 117

1.

Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials.

Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, Kalyandrug S, Christian M, Arbuck S, Hollingshead M, Sausville EA.

Br J Cancer. 2001 May 18;84(10):1424-31.

2.

Therapeutic and pharmacological studies of tetrachloro(d,l-trans)1,2-diaminocyclohexane platinum (IV) (tetraplatin), a new platinum analogue.

Rahman A, Roh JK, Wolpert-DeFilippes MK, Goldin A, Venditti JM, Woolley PV.

Cancer Res. 1988 Apr 1;48(7):1745-52.

3.

Relationship between in vitro tumor stem cell assay and in vivo antitumor activity using the P388 leukemia.

Marsh JC, Shoemaker RH, Salmon SE, Kern DH, Venditti JM.

Int J Cell Cloning. 1988 Jan;6(1):60-8.

PMID:
3339266
4.

Application of a human tumor colony-forming assay to new drug screening.

Shoemaker RH, Wolpert-DeFilippes MK, Kern DH, Lieber MM, Makuch RW, Melnick NR, Miller WT, Salmon SE, Simon RM, Venditti JM, et al.

Cancer Res. 1985 May;45(5):2145-53.

5.

The effectiveness of the anthracycline analog 4'-epidoxorubicin in the treatment of experimental tumors: a review.

Goldin A, Venditti JM, Geran R.

Invest New Drugs. 1985;3(1):3-21. Review.

PMID:
3886588
6.

Potentials and drawbacks of the human tumor stem cell assay.

Shoemaker RH, Wolpert-DeFilippes MK, Venditti JM.

Behring Inst Mitt. 1984 May;(74):262-72.

PMID:
6477356
7.

Current NCI preclinical antitumor screening in vivo: results of tumor panel screening, 1976-1982, and future directions.

Venditti JM, Wesley RA, Plowman J.

Adv Pharmacol Chemother. 1984;20:1-20. Review. No abstract available.

PMID:
6398966
8.

The National Cancer Institute antitumor drug discovery program, current and future perspectives: a commentary.

Venditti JM.

Cancer Treat Rep. 1983 Sep;67(9):767-72. No abstract available.

PMID:
6883352
9.

Use of the KB cell line for in vitro cytotoxicity assays.

Shoemaker RH, Abbott BJ, Macdonald MM, Mayo JG, Venditti JM, Wolpert-DeFilippes MK.

Cancer Treat Rep. 1983 Jan;67(1):97. No abstract available.

PMID:
6616499
10.

Calorie restriction: effect on growth of human tumors heterotransplanted in nude mice.

Giovanella BC, Shepard RC, Stehlin JS, Venditti JM, Abbott BJ.

J Natl Cancer Inst. 1982 Feb;68(2):249-57.

PMID:
6278189
11.

Preclinical drug development: rationale and methods.

Venditti JM.

Semin Oncol. 1981 Dec;8(4):349-61. No abstract available.

PMID:
7323809
12.

Current results of the screening program at the Division of Cancer Treatment, National Cancer Institute.

Goldin A, Venditti JM, Macdonald JS, Muggia FM, Henney JE, Devita VT Jr.

Eur J Cancer. 1981 Feb;17(2):129-42. No abstract available.

PMID:
6894902
13.

A prospective screening program: current screening and its status.

Goldin A, Venditti JM.

Recent Results Cancer Res. 1981;76:176-91. No abstract available.

PMID:
7232850
14.

Progress report on the screening program at the Division of Cancer Treatment, National Cancer Institute.

Goldin A, Venditti JM.

Cancer Treat Rev. 1980 Dec;7(4):167-76. No abstract available.

PMID:
7214373
15.

The new NCI screen and its implications for clinical evaluation.

Goldin A, Venditti JM.

Recent Results Cancer Res. 1980;70:5-20. No abstract available.

PMID:
7355249
16.

Usefulness and limitations of murine tumor models for the identification of new antitumor agents.

Goldin A, Johnson RK, Venditti JM.

Antibiot Chemother (1971). 1980;28:1-7. Review.

PMID:
6998358
17.

Adequacies and inadequacies in assessing murine toxicity data with antineoplastic agents.

Guarino AM, Rozencweig M, Kline I, Penta JS, Venditti JM, Lloyd HH, Holzworth DA, Muggia FM.

Cancer Res. 1979 Jun;39(6 Pt 1):2204-10.

18.

Design and evaluation of combination chemotherapy trials in experimental animal tumor systems.

Corbett TH, Griswold DP Jr, Wolpert MK, Venditti JM, Schabel FM Jr.

Cancer Treat Rep. 1979 May;63(5):799-801. No abstract available.

PMID:
455319
19.

Circadian dependence of host and tumor responses to cyclophosphamide in mice.

Cardoso SS, Avery T, Venditti JM, Goldin A.

Eur J Cancer. 1978 Sep;14(9):949-54. No abstract available.

PMID:
710487
20.

Effectiveness of clinically active antineoplastic drugs in a surgical-adjuvant chemotherapy treatment regimen using the Lewis Lung (LL) carcinoma.

Merker PC, Wodinsky I, Cantor ML, Venditti JM.

Int J Cancer. 1978 Apr 15;21(4):482-9. No abstract available.

PMID:
78911
21.

Inactivity of DL-amygdalin against human breast and colon tumor xenografts in athymic (nude) mice.

Ovejera AA, Houchens DP, Barker AD, Venditti JM.

Cancer Treat Rep. 1978 Apr;62(4):576-8. No abstract available.

PMID:
418876
23.

Search for new radiation potentiators.

Goldin A, Wodinsky I, Merker PC, Venditti JM.

Int J Radiat Oncol Biol Phys. 1978 Jan-Feb;4(1-2):25-35. No abstract available.

PMID:
632145
24.

Screening at the National Cancer Institute.

Goldin A, Venditti JM, Carter SK.

Natl Cancer Inst Monogr. 1977 Mar;(45):37-48. No abstract available.

PMID:
337155
25.

Comparison of 5-fluorouracil and ftorafur. II. Therapeutic response and development of resistance in murine tumors.

Garibjanian BT, Johnson RK, Kline I, Vadlamudi S, Gang M, Venditti JM, Goldin A.

Cancer Treat Rep. 1976 Sep;60(9):1347-61.

PMID:
797450
26.

Letter: Results of butocin (NSC-172755) testing against tumors in animals.

Venditti JM.

Cancer Treat Rep. 1976 Mar;60(3):215. No abstract available.

PMID:
1260774
27.

Antitumor activity of DTIC (NSC-45388) in animals.

Venditti JM.

Cancer Treat Rep. 1976 Feb;60(2):135-40. No abstract available.

PMID:
1260771
28.

Potentiation of actinomycin D or adriamycin antitumor activity with DNA.

Marks TA, Venditti JM.

Cancer Res. 1976 Feb;36(2 Pt 1):496-504.

29.

Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943).

Woodman RJ, Cysyk RL, Kline I, Gang M, Venditti JM.

Cancer Chemother Rep. 1975 Jul-Aug;59(4):689-95.

PMID:
1175163
30.

Combination radiotherapy and chemotherapy for P388 lymphocytic leukemia in vivo.

Wodinsky I, Swiniarski J, Kensler CJ, Venditti JM.

Cancer Chemother Rep 2. 1974 Mar;4(1):73-97. No abstract available.

PMID:
4826500
31.

Protection with N-acetyl-L-cysteine (NSC-111180) against isophosphamide (NSC-109724) toxicity and enhancement of therapeutic effect in early murine L1210 leukemia.

Kline I, Gang M, Woodman RJ, Cysyk RL, Venditti JM.

Cancer Chemother Rep. 1973 Sep-Oct;57(3):299-304. No abstract available.

PMID:
4751256
33.

Immunity to a TA3 tumor subline that grows in allogeneic hosts elicited by strain-specific TA3 tumor cells.

Lippman MM, Venditti JM, Kline I, Elam DL.

Cancer Res. 1973 Apr;33(4):679-84. No abstract available.

35.

Evaluation of antileukemic agents in advanced leukemia L1210 in mice. X.

Kline I, Gang M, Tyrer DD, Venditti JM, Artis EW, Goldin A.

Cancer Chemother Rep 2. 1972 Nov;3(1):1-69. No abstract available.

PMID:
4660732
36.

Methanesulfonates: the relationship of structure to antitumor activity.

Sandberg JS, Wood HB Jr, Engle RR, Venditti JM, Goldin A.

Cancer Chemother Rep 2. 1972 Nov;3(1):137-229. No abstract available.

PMID:
4350012
37.

A quick reference chart on cross resistance between anticancer patients.

Skipper HE, Hutchison DJ, Schabel FM Jr, Schmidt LH, Goldin A, Brockman RW, Venditti JM, Wodinsky I.

Cancer Chemother Rep. 1972 Aug;56(4):493-8. No abstract available.

PMID:
5081592
38.
39.

Influence of the stage of advancement of leukemia L1210 in mice on the optimal schedule of treatment of cytosine arabinoside (NSC-63878).

Kline I, Woodman RJ, Gang M, Sirica A, Venditti JM, Goldin A.

Cancer Chemother Rep. 1972 Jun;56(3):327-34.

PMID:
19051491
40.

Working session report: in vivo-in vitro screening.

Venditti JM.

Cancer Chemother Rep 3. 1972 May;3(1):57-62. No abstract available.

PMID:
5049711
41.

The effect of phenobarbital or 2-diethylaminoethyl-2,2-diphenylvalerate on the activation of cyclophosphamide in vivo.

Field RB, Gang M, Kline I, Venditti JM, Waravdekar VS.

J Pharmacol Exp Ther. 1972 Feb;180(2):475-83. No abstract available.

PMID:
5010684
42.

Enhanced response of leukemia (L1210) mice to combination chemotherapy with 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (NSC-45388) and 5-fluorouracil (NSC-19893).

Kline I, Woodman RJ, Gang M, Waravdekar VS, Goldin A, Venditti JM.

Cancer. 1971 Jun;27(6):1363-8. No abstract available.

PMID:
5088212
43.

Evaluation of antileukemic agents in advanced leukemia L1210 in mice. IX.

Kline I, Gang M, Tyrer DD, Venditti JM, Artis EW, Goldin A.

Cancer Chemother Rep 2. 1971 Apr;2(1):65-133. No abstract available.

PMID:
5565539
45.

Combination therapy studies with L-asparaginase (NSC-109229) and other antitumor agents.

Jacobs SP, Wodinsky I, Kensler CJ, Venditti JM.

Cancer Chemother Rep. 1970 Oct;54(5):329-35. No abstract available.

PMID:
5514622
46.

Glutamine antagonists in chemotherapy.

Livingston RB, Venditti JM, Cooney DA, Carter SK.

Adv Pharmacol Chemother. 1970;8:57-120. Review. No abstract available.

PMID:
4400179
47.

Sequential chemotherapy with cyclophosphamide (NSC-26271) and cytosine arabinoside (NSC-63878) in mice with advanced leukemia L1210.

Hoffman GS, Kline I, Gang M, Tyrer DD, Goldin A, Mantel N, Venditti JM.

Cancer Chemother Rep. 1969 Oct;53(5):265-71. No abstract available.

PMID:
5377613
48.

Effectiveness of antileukemic agents in mice inoculated with a leukemia L1210 variant resistant to 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196).

Tyrer DD, Kline I, Gang M, Goldin A, Venditti JM.

Cancer Chemother Rep. 1969 Sep;53(4):229-41. No abstract available.

PMID:
5384463
49.

Influence of treatment schedules and route of administration on the chemotherapy of murine leukemia L1210 with 5(or 4)-[3,3-bis( 2-chloroethyl)-1-triazeno]imidazole-4(or 5)-carboxamide (NSC-82196).

Hoffman G, Kline I, Gang M, Tyrer DD, Venditti JM, Goldin A.

Cancer Chemother Rep. 1968 Dec;52(7):715-24. No abstract available.

PMID:
5743709
50.

Effectiveness of cytosine arabinoside therapy on leukemia (L-1210) of the central nervous system in mice arising during methotrexate treatment.

Kline I, Tyrer DD, Venditti JM, Waravdekar VS, Gang M.

Gan. 1968 Dec;59(6):527-35. No abstract available.

PMID:
4305660

Supplemental Content

Loading ...
Support Center